Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

New York, New York–(Newsfile Corp. – June 17, 2021) – PCG Digital — Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECH^TM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology “did not negate the known efficacy of those compounds.”

“This test is conducted as a pass/fail,” said Chris Bunka, CEO of Lexaria Bioscience. “We needed to know if DehydraTECH^TM interferes in any way with the effects these drugs have on the virus. It doesn’t give us any direct score on “how well” it works or does not, just a yes-no. The next step is to move on to in vivo efficacy testing in animals and then eventually humans.”

That’s good news on two fronts for Lexaria. The first and most obvious is that DehydraTECH^TM works with these important antivirals. The second is that it opens the door to an antiviral market projected to be worth USD$44 billion by 2026. The company is not limiting its scope in this area to only COVID-19 drugs. Several antivirals will be tested in the same manner.

Remdesivir, which is sold under the brand name Veklury, is a broad-spectrum antiviral that was originally developed to treat hepatitis C. It was approved and authorized for emergency use by the FDA as a therapeutic treatment for COVID-19 in 2020. Lexaria would like to emphasize that the use of DehydraTECH^TM with Remdesivir does not create a “cure” for COVID-19.

Ebastine is an antihistamine that is administered orally. It’s used for treatment of allergic rhinitis and chronic idiopathic urticaria. In some countries it is also used for relief from mosquito bites or atopic dermatitis. It’s been in medical use since 1990 and is available in 10mg to 20mg tablets, fast-dissolving tablets, and as a pediatric syrup.

Remdesivir and Ebastine both face bioavailability challenges when administered orally, thus limiting their commercial potential. Lexaria hopes to change this with its technology.

This week, Lexaria announced it had measured circulating drug levels of DehydraTECH-enabled Remdesivir and Ebastine twice or even three times higher than concentration-matched controls without DehydraTECH. Mr. Bunka described the outcome as “the best results Lexaria has ever generated demonstrating our technology’s ability to more effectively deliver antiviral drugs when taken orally.”

Lexaria Has a Track Record of Success with DehydraTECH^TM

Antivirals are not the only market where DehydraTECH^TM has been proven to be effective. In 2018, Lexaria ran a human clinical trial on hypertension using DehydraTECH^TM CBD. The results showed a 5% drop in blood pressure after just one 90mg dose. CBD administered using Lexaria’s patented dehydration process was shown to deliver 300%+ more CBD in under 30 minutes.

Those results were the first step into a $30 billion antihypertensive drug market. Phase I of human clinical trials on the drug, HYPER-H21-1, were completed ahead of schedule this month and the commencement of Phase II was announced this week. The primary objectives of the study are time series blood pressure and heart rate analysis.

Advertisement

Since 2016, DehydraTECH^TM has been consistently proven effective in both CBD and nicotine bio-absorption. Lexaria has licensed the technology to multiple companies in those sectors and has plans to further evaluate DehydraTECH^TM with antivirals, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, human hormones, and vitamins.

The antiviral results, combined with significant progress in the antihypertensive space, increases the likelihood of a Big Pharma partnership for Lexaria. Remdesivir is owned by Gilead Sciences, a company known for acquisitions and partnerships with firms developing cutting edge pharmaceutical technology. Is there synergy there? Time will tell.

Disclaimer

This communication was produced by PCG Digital LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG is compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information.

The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” unless you can afford to lose your entire investment. We urge investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.

For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.

Contact: info@pcgadvisory.com

Advertisement

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87788